Process cost and facility considerations in the selection of primary cell culture clarification technology

The bioreactor volume delineating the selection of primary clarification technology is not always easily defined. Development of a commercial scale process for the manufacture of therapeutic proteins requires scale‐up from a few liters to thousands of liters. While the separation techniques used for protein purification are largely conserved across scales, the separation techniques for primary cell culture clarification vary with scale. Process models were developed to compare monoclonal antibody production costs using two cell culture clarification technologies. One process model was created for cell culture clarification by disc stack centrifugation with depth filtration. A second process model was created for clarification by multi‐stage depth filtration. Analyses were performed to examine the influence of bioreactor volume, product titer, depth filter capacity, and facility utilization on overall operating costs. At bioreactor volumes <1,000 L, clarification using multi‐stage depth filtration offers cost savings compared to clarification using centrifugation. For bioreactor volumes >5,000 L, clarification using centrifugation followed by depth filtration offers significant cost savings. For bioreactor volumes of ∼2,000 L, clarification costs are similar between depth filtration and centrifugation. At this scale, factors including facility utilization, available capital, ease of process development, implementation timelines, and process performance characterization play an important role in clarification technology selection. In the case study presented, a multi‐product facility selected multi‐stage depth filtration for cell culture clarification at the 500 and 2,000 L scales of operation. Facility implementation timelines, process development activities, equipment commissioning and validation, scale‐up effects, and process robustness are examined. © 2013 The Authors. American Institute of Chemical Engineers Biotechnol. Prog., 29:1239–1245, 2013

[1]  Brian D. Kelley,et al.  Purification Strategies to Process 5 g/L Titers of Monoclonal Antibodies : Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes , 2009 .

[2]  Andrew L. Zydney,et al.  Bioprocess membrane technology , 2007 .

[3]  Frank Riske,et al.  The use of chitosan as a flocculant in mammalian cell culture dramatically improves clarification throughput without adversely impacting monoclonal antibody recovery. , 2007, Journal of biotechnology.

[4]  Anurag S Rathore,et al.  Comparison of different options for harvest of a therapeutic protein product from high cell density yeast fermentation broth , 2006, Biotechnology and bioengineering.

[5]  Brian Kelley,et al.  Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.

[6]  Klaus Tarrach,et al.  Depth filtration: Cell clarification of bioreactor offloads , 2006 .

[7]  H Baldascini,et al.  Impact of clarification strategy on chromatographic separations: Pre‐processing of cell homogenates , 2008, Biotechnology and bioengineering.

[8]  N. Slater,et al.  Characterisation of a generic monoclonal antibody harvesting system for adsorption of DNA by depth filters and various membranes , 1999, Bioseparation.

[9]  David W. Roush,et al.  Impact of Cell Density and Viability on Primary Clarification of Mammalian Cell Broth An Analysis Using Disc-Stack Centrifugation and Charged Depth Filtration , 2007 .

[10]  C. F. van der Walle,et al.  Therapeutic antibodies: market considerations, disease targets and bioprocessing. , 2013, International journal of pharmaceutics.

[11]  N Hutchinson,et al.  Shear stress analysis of mammalian cell suspensions for prediction of industrial centrifugation and its verification , 2006, Biotechnology and bioengineering.

[12]  D. Roush,et al.  Advances in Primary Recovery: Centrifugation and Membrane Technology , 2008, Biotechnology progress.

[13]  John Paul Smelko,et al.  Effects of solution environment on mammalian cell fermentation broth properties: Enhanced impurity removal and clarification performance , 2011, Biotechnology and bioengineering.

[14]  Klaus Tarrach,et al.  Cell clarification of bioreactor offloads , 2006 .

[15]  Abhinav A Shukla,et al.  Exploitation of the Adsorptive Properties of Depth Filters for Host Cell Protein Removal during Monoclonal Antibody Purification , 2006, Biotechnology progress.

[16]  W Berthold,et al.  Assessment of a disc stack centrifuge for use in mammalian cell separation , 1995, Biotechnology and bioengineering.

[17]  Matthew Westoby,et al.  Modeling industrial centrifugation of mammalian cell culture using a capillary based scale‐down system , 2011, Biotechnology and bioengineering.

[18]  Suzanne S Farid,et al.  Process economics of industrial monoclonal antibody manufacture. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  Florian M. Wurm,et al.  Recombinant Protein Production Yields from Mammalian Cells : Past, Present, and Future , 2008 .

[20]  Herb Lutz,et al.  Considerations for Scaling-up Depth Filtration of Harvested Cell Culture Fluid , 2009 .